1. BCL2 gene abnormalities define distinct clinical subsets of follicular lymphoma.
- Author
-
Goodlad, J. R., Batstone, P. J., Hamilton, D. A., Kernohan, N. M., Levison, D. A., and White, J. M.
- Subjects
- *
ESTRONE , *LYMPHOMAS , *SKIN , *HISTOPATHOLOGY , *TUMORS - Abstract
Aims: Follicular lymphoma (FL) arising primarily in the skin has recently been proposed as a distinct entity on the basis of a low incidence of t(14;18)(q32;q21) and bcl-2 expression, with a very high percentage of patients surviving more than 5 years. However, cases of t(14;18)(q32;q21)-positive primary cutaneous FL (PCFL) and examples of t(14;18)(q32;q21)-negative FL at nodal and other extranodal sites, are well documented. The aim of this study was to test the hypothesis that there is a subtype of FL lacking t(14;18)(q32;q21), which preferentially involves certain sites but is not restricted by anatomical location. Methods and results: A cohort of 47 stage 1 FL was stratified according to the presence or absence of t(14;18)(q32;q21) using conventional cytogenetics, polymerase chain reaction and interphase fluorescence in situ hybridization. Compared with t(14;18)(q32;q21)-positive cases, FL lacking the translocation were less likely to express CD10 or bcl-2 ( P < 0.01), made up a significantly greater proportion of cases arising at extranodal sites ( P < 0.001) and had a significantly better overall and disease-specific 5-year survival ( P < 0.01). Conclusions: These results support the concept of a subtype of FL lacking t(14;18)(q32;q21), characterized by low-intensity bcl-2 expression, a predilection for extranodal sites, particularly the skin, and a more favourable outcome than t(14;18)(q32;q21)-positive FL. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF